Good Lifestyle

Ozempic and Wegovy both made the headlines recently, helping people achieve difficult weight loss goals and managing their diabetes. But despite these positive advantages, like other treatments, there is also Associated side effects , with more patients reporting uncomfortable and even debilitating unwanted events. Now a new study suggests that drugs like Ozempic and Wegovy can be linked to three severe stomach conditions. Read the rest to discover what researchers have found.

In relation: The ozempic patient reveals "a new" atrocious "side effect .

While the Ozempic is only indicated for the treatment of type 2 diabetes, Wegovy is approved for the Obesity treatment , but both are often prescribed for weight loss. Drugs are peptide 1 agonists of the glucagon type (GLP-1), who slow down digestion and decrease appetite, thus helping to lose books. But they can also cause problems if digestion slows down too much.

Previous studies have found that these drugs increase the risk of gastrointestinal problems (GI) in diabetic patients, and these patients have an increased risk for certain conditions even if they are not Take GLP-1. In light of this, a New study published in Jama This week has studied risks in non-diabetic patients using weight loss drugs (especially semaglutide, active ingredient in ozempic and wegovy, and liraglutide, another GLP-1). One of the authors of the study, Mohit Sodhi , told CNBC that researchers wanted " Remove diabetes from the equation . ""

Interestingly, when you are considering health insurance complaints of 16 million non-diabetic patients in the United States under GLP-1, the researchers found that they were also at risk for the three rare and severe stomach conditions .

In relation: Buyers turn away from Walmart - and Ozempic can be blamed .

There have been a lot of discussions on stomach paralysis In patients taking ozempic and Wegovy. The condition, officially known as gastreresis , affects the nerves and muscles of the stomach, slowing down and weakening the muscular contractions necessary to digest and pass food through the intestines, according to the Cleveland Clinic. The condition leads to painful symptoms such as cyclical vomiting, which can then cause dehydration.

Although GI problems are cited on warning labels for drugs like Ozempic and Wegovy, stomach paralysis is not. However, the new study, conducted by researchers from the University of British Columbia, suggests that it should be because the results have shown that patients had an increased risk of developing the condition.

The higher risk has been determined by comparing patients taking GLP-1 to those who take bupropion-naltrexone, another weight loss treatment that passes through the brand Relax . According to study data and CNBC, those of GLP-1 had a three-time risk of stomach paralysis than those of the Bupropion-Naltrexone.

And although it may seem a small number, another author of the study, epidemiologist Mahyar etminan , said to CNN: "When you have millions of people Using these drugs, you know, a risk of 1% always results in many people who can live these events. ""

In relation: The ozempic patient reveals "crazy and frightening" side effects that made him arrest .

Patients taking GLP-1 for weight loss also had an increased risk of intestinal obstruction, suggest study data. Compared to those of the Bpropion-Naltrexone, those of GLP-1 had a risk four times higher of intestinal obstruction. AE0FCC31AE342FD3A1346EBB1F342FCB

Speaking of this, the Food and Drug Administration of the United States (FDA) Label update For Ozempic to recognize Ileus, which is the medical term for "movement somewhere in the intestines which leads to accumulation and potential locking food equipment, "explains the HR on his website." An ileus can lead to intestinal obstruction. This means that no food, gas or liquid material can pass. ""

In relation: The woman with an incurable stomach statement says that Ozempic "is not worth that".

Non -diabetic patients also had an increased risk of inflammation of the pancreas, officially known as pancreatitis. Patients under GLP-1 had a nine times higher risk of this condition than those of Bupropion-Naltrexone.

As an intestinal obstruction, the drug also risk of pancreatitis .

In relation: An ozempic manufacturer continued its alleged side effect by sending patients to ER .

The study also examined bile disease , which "refers to diseases affecting the bile ducts, the gallbladder and other structures involved in the production and transport of bile", according to the George Washington University Hospital. Patients taking the GLP-1 had no increased risk for these conditions compared to those of the Bupropion-Naltrexone.

A spokesperson for Novo Nordisk, the manufacturer of Ozempic and Wegovy, reiterated to Better life that certain gastrointestinal side effects cited in the study are already noted on labels.

"[Novo Nordisk] is behind the safety and efficiency of all our GLP-1 drugs when used in accordance with the labeling of the product and approved indications," said the spokesperson in an email. “We recommend that patients take these drugs for their approved indications and under the supervision of a health professional. . ""

Be that as it may, the researchers hope that their results could be lit for patients taking medication to lose weight.

"We are all great supporters for the informed consent of the patient," Sodhi told CNBC. "If someone had decided to take a GLP-1 to lose weight, we encourage them to have a conversation with their supplier on how it can help them achieve their goals. But they should also be informed of the drawbacks potential to take this medication. "

The study authors, however, noted limitations, in particular that users of GLP-1 agonists who were assessed had an obesity registration without diabetes, but it was "uncertain" if the GLP-1 were used for Weight loss in each situation. In addition, health insurance complaints were dated between 2006 and 2020, which was before Wegovy was on the market.

In relation: For more information, register for our daily newsletter .

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.